Redeye: Dignitana Q4’23 - Positive momentum into 2024
Redeyes’ long-term view of Dignitana is intact even if the sales progression was softer than we expected. The reimbursement process takes time; however, there are positive signs about a good start in the US regarding installed systems. The costs were again well contained, and with a more robust gross margin, the results came roughly in line with expectations. To be cautious, we have lowered our sales estimates for 2024/25e. The growth is still expected to be strong, albeit at a lower rate. With the downward adjustments, our new Base case value is SEK 9.5 (10) per share, with a fair value range of SEK 2.9 to 20 per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/